| Website | alethiabio.com |
| Category | BioTech |
| Phone | 514.858.7666 |
| info@alethiabio.com | |
| Employees | |
| Founded | 2002 |
| TOTAL | $13.9M |
| FUNDING TOTAL | $13.9M |
| Series A, 9/10 AgeChem Venture Fund BDC Venture Capital GO Capital Fund Epicentre Technologies | $9.2M |
| Series B, 11/12 AgeChem Venture Fund BDC Venture Capital GO Capital Fund | $4.7M |
Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.
